Treatment of inflammatory dermatoses with novel biologic agents: a primer.
Nussbaum
Rachel
R
Laboratory for Investigative Dermatology, Rockefeller University, New York, NY, USA.
Krueger
James G
JG
D000077944:Alefacept; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use*; D000922:Immunotoxins / Q000627:therapeutic use*; D000069285:Infliximab; D011565:Psoriasis / Q000188:drug therapy / Q000276:immunology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D012871:Skin Diseases / Q000188:drug therapy* / Q000276:immunology
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007155:Immunologic Factors; D000922:Immunotoxins; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D000069285:Infliximab; D000077944:Alefacept; D000068800:Etanercept